MX390651B - Compuestos para el tratamiento de trastornos hipoproliferativos - Google Patents
Compuestos para el tratamiento de trastornos hipoproliferativosInfo
- Publication number
- MX390651B MX390651B MX2018005158A MX2018005158A MX390651B MX 390651 B MX390651 B MX 390651B MX 2018005158 A MX2018005158 A MX 2018005158A MX 2018005158 A MX2018005158 A MX 2018005158A MX 390651 B MX390651 B MX 390651B
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- compounds
- hypoproliferative disorders
- disorders
- hypoproliferative
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 abstract 2
- 102100033145 Cyclin-dependent kinase 19 Human genes 0.000 abstract 1
- 102100024456 Cyclin-dependent kinase 8 Human genes 0.000 abstract 1
- 101000944345 Homo sapiens Cyclin-dependent kinase 19 Proteins 0.000 abstract 1
- 101000980937 Homo sapiens Cyclin-dependent kinase 8 Proteins 0.000 abstract 1
- 230000001195 anabolic effect Effects 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1551419 | 2015-11-03 | ||
| PCT/EP2016/076550 WO2017076968A1 (en) | 2015-11-03 | 2016-11-03 | Compounds for treatment of hypoproliferative disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018005158A MX2018005158A (es) | 2019-05-16 |
| MX390651B true MX390651B (es) | 2025-03-21 |
Family
ID=57326350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018005158A MX390651B (es) | 2015-11-03 | 2016-11-03 | Compuestos para el tratamiento de trastornos hipoproliferativos |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11471446B2 (https=) |
| EP (1) | EP3370720A1 (https=) |
| JP (1) | JP6977238B2 (https=) |
| KR (1) | KR20180073600A (https=) |
| CN (1) | CN108348509A (https=) |
| AU (1) | AU2016348659B2 (https=) |
| BR (1) | BR112018008931A8 (https=) |
| IL (1) | IL258593B (https=) |
| MX (1) | MX390651B (https=) |
| WO (1) | WO2017076968A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12281080B2 (en) | 2018-08-21 | 2025-04-22 | University Of South Carolina | Quinoline-based compounds and methods of inhibiting CDK8/19 |
| US11014906B2 (en) | 2018-08-21 | 2021-05-25 | University Of South Carolina | Quinoline-based compounds and methods of inhibiting CDK8/19 |
| CA3128377A1 (en) * | 2019-02-01 | 2020-08-06 | University Of South Carolina | Bicyclic pyridine compositions and methods of using the same for cancer therapy |
| US20220226343A1 (en) * | 2019-05-21 | 2022-07-21 | University Of South Carolina | 3-amino-4-[4-[4 (dimethylcarbamoyl) phenyl]-1,4-diazepan-1-yl]thieno[2,3-b]pyridine-2-carboxamide for use in cancer therapy and formulations comprising the same |
| GB202208226D0 (en) * | 2022-06-06 | 2022-07-20 | Royal Veterinary College | Method and treatment for osteoarthritis and diseases of chondrocyte hypertrophy |
| WO2023241627A1 (en) * | 2022-06-15 | 2023-12-21 | Insilico Medicine Ip Limited | Cdk8/19 dual inhibitors and methods of use thereof |
| WO2024193640A1 (zh) * | 2023-03-22 | 2024-09-26 | 上海齐鲁制药研究中心有限公司 | Cdk抑制剂 |
| TW202449143A (zh) * | 2023-04-18 | 2024-12-16 | 國立大學法人京都大學 | 第2型先天性淋巴細胞之製造方法 |
| WO2026004819A1 (ja) * | 2024-06-24 | 2026-01-02 | 国立大学法人 長崎大学 | 骨形成促進用組成物 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1513516T3 (da) | 2002-06-06 | 2009-10-19 | Boehringer Ingelheim Pharma | Substitueret 3-amino-thieno(2,3-b)-pyridin-2-carboxylsyreamid-forbindelser og fremgangsmåder til fremstilling og deres anvendelser |
| AU2005233437A1 (en) | 2004-04-12 | 2005-10-27 | Sankyo Company, Limited | Thienopyridine derivatives |
| US8598344B2 (en) | 2009-11-30 | 2013-12-03 | Senex Biotechnology | CDKI pathway inhibitors and uses thereof |
| US20140309224A1 (en) * | 2011-09-13 | 2014-10-16 | Roninson Igor B | TREATMENT OF DISEASES OR DISORDERS CAUSED BY INDUCED NFkB TRANSCRIPTIONAL ACTIVITY |
| UA117342C2 (uk) | 2012-02-02 | 2018-07-25 | Сенекс Біотекнолоджи Інк. | Селективні інгібітори cdk8/cdk19 та їх застосування як протиметастатичних та хіміопрофілактичних засобів у способах лікування раку |
| WO2013138101A2 (en) | 2012-03-16 | 2013-09-19 | Children's Medical Center Corporation | Calmodulin inhibitors for the treatment of ribosomal disorders and ribosomapathies |
| EP2888232A1 (en) | 2012-08-23 | 2015-07-01 | F. Hoffmann-La Roche AG | Novel phenyl-pyridine/pyrazine amides for the treatment of cancer |
| GB201220157D0 (en) * | 2012-11-08 | 2012-12-26 | Selvita Sa | Substitute tricyclic benzimidazoles as kinase inhibitors |
| JP2016501251A (ja) | 2012-12-10 | 2016-01-18 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | がんの治療のための新規二環フェニル−ピリジン／ピラジン |
| WO2014106606A1 (en) | 2013-01-05 | 2014-07-10 | F. Hoffmann-La Roche Ag | Nove phenyl/pyridine series substitued by hydroxyethylamino for the treatment of cancer |
| WO2014154723A1 (en) | 2013-03-29 | 2014-10-02 | F. Hoffmann-La Roche Ag | Novel pyrrole derivatives for the treatment of cancer |
| WO2014194245A2 (en) * | 2013-05-31 | 2014-12-04 | Nimbus Iris, Inc. | Cdk8 inhibitors and uses thereof |
| JP6434989B2 (ja) * | 2014-03-27 | 2018-12-05 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | ピリジルピペリジン |
-
2016
- 2016-11-03 MX MX2018005158A patent/MX390651B/es unknown
- 2016-11-03 EP EP16797472.4A patent/EP3370720A1/en not_active Withdrawn
- 2016-11-03 WO PCT/EP2016/076550 patent/WO2017076968A1/en not_active Ceased
- 2016-11-03 KR KR1020187013367A patent/KR20180073600A/ko not_active Withdrawn
- 2016-11-03 US US15/772,633 patent/US11471446B2/en active Active
- 2016-11-03 CN CN201680063630.0A patent/CN108348509A/zh active Pending
- 2016-11-03 JP JP2018541543A patent/JP6977238B2/ja active Active
- 2016-11-03 BR BR112018008931A patent/BR112018008931A8/pt not_active Application Discontinuation
- 2016-11-03 AU AU2016348659A patent/AU2016348659B2/en active Active
-
2018
- 2018-04-10 IL IL258593A patent/IL258593B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| US20190111034A1 (en) | 2019-04-18 |
| CN108348509A (zh) | 2018-07-31 |
| AU2016348659A1 (en) | 2018-05-31 |
| BR112018008931A8 (pt) | 2019-02-26 |
| CA3002495A1 (en) | 2017-05-11 |
| EP3370720A1 (en) | 2018-09-12 |
| JP2018532784A (ja) | 2018-11-08 |
| AU2016348659B2 (en) | 2022-07-28 |
| IL258593B (en) | 2021-04-29 |
| IL258593A (en) | 2018-06-28 |
| WO2017076968A1 (en) | 2017-05-11 |
| JP6977238B2 (ja) | 2021-12-08 |
| BR112018008931A2 (pt) | 2018-11-06 |
| KR20180073600A (ko) | 2018-07-02 |
| MX2018005158A (es) | 2019-05-16 |
| US11471446B2 (en) | 2022-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX390651B (es) | Compuestos para el tratamiento de trastornos hipoproliferativos | |
| CL2016002027A1 (es) | Ciclopropilamina como inhibidor de la lsd1 | |
| MX2015012502A (es) | Inhibidores de proteina cinasa dependiente de adn. | |
| EA201692529A1 (ru) | Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов | |
| CL2017000864A1 (es) | Composiciones y métodos de uso para tratar trastornos metabólicos | |
| ZA201605715B (en) | Cyclopropylamines as lsd1 inhibitors | |
| CL2015002658A1 (es) | Derivados de 2, 3 - disustituto 1- acil -4 amino - 1,2,3,4 tetrahidroquinilina y su uso como inhibidores de bromodominio | |
| NI201600071A (es) | Compuestos de inhibidor de autotaxina | |
| EA201692313A1 (ru) | Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ | |
| CL2015001985A1 (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim. | |
| MX2015011898A (es) | Compuestos de pirazolo y usos de los mismos. | |
| MX371108B (es) | Pirimidopirimidinonas utiles como iniciadores de wee-1 cinasa. | |
| MX381640B (es) | Metodos y compuestos agonistas de gip. | |
| ECSP14030779A (es) | Inhibidores del nampt | |
| UY37018A (es) | Inhibidores bicíclicos de pad4 | |
| GT201300209A (es) | Compuestos y composiciones como inhibidores de la trk | |
| ECSP17013903A (es) | Protein kinase c inhibitors and methods of their use | |
| EA201691032A1 (ru) | Производные изохромена в качестве ингибиторов фосфоинозитид-3-киназ | |
| UY37017A (es) | Inhibidores aza-bencimidazol de pad4 | |
| MX2015011281A (es) | Composiciones de inh-c1 y metodos para la prevencion y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa. | |
| CL2015002897A1 (es) | Inhibidores de bace1 | |
| CO7151543A2 (es) | Combinaciones terapéuticas y métodos para tratar el melanoma | |
| MX374385B (es) | Apilimod para uso en el tratamiento de melanoma. | |
| CL2016002839A1 (es) | Derivados de carboxamida | |
| MX381544B (es) | Composición de células estromales mesenquimatosas para usare en el tratamiento de la sepsis en un sujeto. |